Lindenwold Advisors INC Sells 575 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Lindenwold Advisors INC lowered its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 17.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,780 shares of the medical instruments supplier’s stock after selling 575 shares during the period. Lindenwold Advisors INC’s holdings in LeMaitre Vascular were worth $256,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in LMAT. Smartleaf Asset Management LLC increased its position in shares of LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC increased its position in shares of LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 117 shares in the last quarter. KBC Group NV increased its position in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 410 shares in the last quarter. Empowered Funds LLC bought a new position in LeMaitre Vascular during the 4th quarter worth about $150,000. Finally, SG Americas Securities LLC bought a new position in LeMaitre Vascular during the 4th quarter worth about $158,000. Institutional investors own 84.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LMAT. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Lake Street Capital lifted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, February 28th. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective for the company. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $95.25.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Down 0.2 %

NASDAQ LMAT opened at $84.91 on Wednesday. The company has a 50 day moving average of $94.90 and a 200-day moving average of $94.60. The company has a market cap of $1.92 billion, a price-to-earnings ratio of 46.40, a PEG ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. The business had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.94%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date is Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.